|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
ICI 118551 inhibits the reaction [Formoterol Fumarate results in decreased expression of ACTA2 protein] Formoterol Fumarate results in decreased expression of ACTA2 mRNA; Formoterol Fumarate results in decreased expression of ACTA2 protein |
CTD |
PMID:21603974 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Formoterol Fumarate binds to and results in increased activity of ADRB1 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB1 protein] |
CTD |
PMID:14730417 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases activity increases phosphorylation affects expression |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Dactinomycin inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA]; Formoterol Fumarate binds to and results in increased activity of ADRB2 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA] Formoterol Fumarate results in increased activity of ADRB2 protein Formoterol Fumarate results in increased phosphorylation of ADRB2 protein |
CTD |
PMID:14722251 PMID:14730417 PMID:16980553 PMID:20061444 PMID:24705868 PMID:34601065 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Formoterol Fumarate binds to and results in increased activity of ADRB3 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Formoterol Fumarate results in decreased expression of BCL2 mRNA; Formoterol Fumarate results in decreased expression of BCL2 protein |
CTD |
PMID:14687023 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CCL5 protein |
CTD |
PMID:15679717 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
ISO |
Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]] |
CTD |
PMID:18076728 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CSF2 protein |
CTD |
PMID:15679717 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein] |
CTD |
PMID:18076728 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein] |
CTD |
PMID:18076728 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
Formoterol Fumarate results in increased expression of IGF1 mRNA |
CTD |
PMID:36822333 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
EXP |
Formoterol Fumarate results in decreased expression of IL10 mRNA |
CTD |
PMID:16908771 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
EXP |
desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 mRNA]]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 mRNA]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 protein] |
CTD |
PMID:26003274 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate] |
CTD |
PMID:20061444 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP ISO |
desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]]; desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein]]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein]; Formoterol Fumarate promotes the reaction [desisobutyrylciclesonide inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]] Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]] |
CTD |
PMID:18076728 PMID:26003274 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
affects expression increases expression multiple interactions |
EXP |
Formoterol Fumarate affects the expression of IL6 mRNA; Formoterol Fumarate affects the expression of IL6 protein Formoterol Fumarate results in increased expression of IL6 mRNA Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:10525314 PMID:11096136 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Formoterol Fumarate results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; Formoterol Fumarate results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:15603589 PMID:16980553 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Formoterol Fumarate results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:15603589 PMID:16980553 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[Formoterol Fumarate co-treated with desisobutyrylciclesonide] inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK8 protein]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:26003274 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:26003274 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Budesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]; Formoterol Fumarate inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]; Formoterol Fumarate promotes the reaction [Budesonide inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]; Ipratropium promotes the reaction [Formoterol Fumarate inhibits the reaction [Cadmium results in increased activity of MMP9 protein]] |
CTD |
PMID:20826145 PMID:25313925 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases expression |
ISO |
Formoterol Fumarate results in increased expression of MTOR mRNA |
CTD |
PMID:36822333 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[Beclomethasone co-treated with Formoterol Fumarate] affects the localization of NR3C1 protein |
CTD |
PMID:15679717 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
Formoterol Fumarate results in increased expression of PIK3R1 mRNA |
CTD |
PMID:36822333 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases expression |
ISO |
Formoterol Fumarate results in increased expression of PRKAA2 mRNA |
CTD |
PMID:36822333 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Rnase3 |
ribonuclease A family member 3 |
decreases expression |
ISO |
Formoterol Fumarate results in decreased expression of RNASE3 protein |
CTD |
PMID:1443864 |
|
NCBI chr15:24,511,894...24,512,764
Ensembl chr15:24,511,891...24,512,790
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions increases uptake |
ISO |
Budesonide inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; Corticosterone inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; Fluticasone inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [beclomethasone 17-monopropionate results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [Budesonide results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [desisobutyrylciclesonide results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [Fluticasone results in decreased transport of Formoterol Fumarate] |
CTD |
PMID:17920670 PMID:21914487 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]] |
CTD |
PMID:18076728 |
|
NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tnf |
tumor necrosis factor |
affects expression multiple interactions |
EXP ISO |
Formoterol Fumarate affects the expression of TNF mRNA; Formoterol Fumarate affects the expression of TNF protein Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] [TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate] |
CTD |
PMID:10525314 PMID:11096136 PMID:20061444 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases activity |
ISO |
Quetiapine Fumarate results in decreased activity of ABCB1 protein |
CTD |
PMID:16810505 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Quetiapine Fumarate inhibits the reaction [APP protein modified form affects the activity of CAT protein]; Quetiapine Fumarate inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:15948179 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Quetiapine Fumarate results in increased expression of BAX protein |
CTD |
PMID:16462815 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Quetiapine Fumarate results in increased expression of BDNF protein |
CTD |
PMID:17442489 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Quetiapine Fumarate inhibits the reaction [APP protein modified form affects the activity of CAT protein] |
CTD |
PMID:15948179 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
ISO |
Quetiapine Fumarate results in decreased expression of CNR1 protein |
CTD |
PMID:31220554 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
increases expression |
ISO |
Quetiapine Fumarate results in increased expression of CNR2 protein |
CTD |
PMID:31220554 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Carbamazepine promotes the reaction [CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate]; CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate] |
CTD |
PMID:16390352 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Quetiapine Fumarate promotes the reaction [Dopamine binds to DRD2 protein] |
CTD |
PMID:15716360 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [Ketanserin binds to HTR2A protein] |
CTD |
PMID:16314884 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Quetiapine Fumarate inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Quetiapine Fumarate results in decreased activity of KCNH2 protein |
CTD |
PMID:21158687 PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
decreases metabolic processing |
ISO |
Quetiapine Fumarate results in decreased metabolism of MAP1LC3B protein |
CTD |
PMID:31220554 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [Cuprizone results in decreased activity of MBP protein] |
CTD |
PMID:18938062 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]; AM 1241 inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; AM 1241 inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein]; AM 281 inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; AM 281 inhibits the reaction [Quetiapine Fumarate results in increased phosphorylation of MLKL protein]; Quetiapine Fumarate results in increased expression of and affects the localization of MLKL protein; Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein; Rimonabant inhibits the reaction [Quetiapine Fumarate affects the localization of MLKL protein]; Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of and results in increased phosphorylation of MLKL protein] |
CTD |
PMID:31220554 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions affects oxidation decreases activity |
ISO |
Quetiapine Fumarate inhibits the reaction [[MPO protein results in increased metabolism of chlorodimedone] which results in increased abundance of Hypochlorous Acid]; Quetiapine Fumarate inhibits the reaction [MPO protein results in increased abundance of Hypochlorous Acid] MPO protein affects the oxidation of Quetiapine Fumarate Quetiapine Fumarate results in decreased activity of MPO protein |
CTD |
PMID:35575633 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Ndufv2 |
NADH:ubiquinone oxidoreductase core subunit V2 |
increases expression |
EXP |
Quetiapine Fumarate results in increased expression of NDUFV2 mRNA |
CTD |
PMID:19441803 |
|
NCBI chr 9:105,690,454...105,710,669
Ensembl chr 9:105,690,455...105,710,713
|
|
G |
Ngfr |
nerve growth factor receptor |
decreases expression |
EXP |
Quetiapine Fumarate results in decreased expression of NGFR mRNA |
CTD |
PMID:12111809 PMID:16513140 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Prl |
prolactin |
decreases expression increases secretion |
ISO |
Quetiapine Fumarate results in decreased expression of PRL protein Quetiapine Fumarate results in increased secretion of PRL protein |
CTD |
PMID:16379509 PMID:18063941 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions increases expression |
ISO |
AM 281 inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK1 protein]; Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK1 protein] |
CTD |
PMID:31220554 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions increases expression |
ISO |
Rimonabant inhibits the reaction [Quetiapine Fumarate results in increased expression of RIPK3 protein] |
CTD |
PMID:31220554 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:30465787 |
|
NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
ISO EXP |
Quetiapine Fumarate inhibits the reaction [Cuprizone results in decreased activity of SOD1 protein] Quetiapine Fumarate inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA] Quetiapine Fumarate results in increased expression of SOD1 mRNA |
CTD |
PMID:12111809 PMID:12752374 PMID:18938062 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Tenofovir results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
affects expression |
ISO |
Tenofovir affects the expression of ACACB mRNA |
CTD |
PMID:20032539 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Tenofovir results in increased expression of BNIP3L protein |
CTD |
PMID:23640862 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of CASP3 protein]; Tenofovir results in increased expression of and results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein] Tenofovir results in increased expression of CASP3 mRNA |
CTD |
PMID:33146023 PMID:36309141 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [Tenofovir results in increased expression of CASP9 protein] |
CTD |
PMID:33146023 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in decreased activity of CAT protein |
CTD |
PMID:34118364 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression multiple interactions |
ISO |
Tenofovir results in increased expression of CCL20 mRNA Tenofovir results in increased expression of and results in increased secretion of CCL20 protein |
CTD |
PMID:24205323 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of CDKN1A protein Tenofovir results in increased expression of CDKN1A protein |
CTD |
PMID:31545371 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Tenofovir results in decreased activity of CYP2E1 protein |
CTD |
PMID:17162464 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddx3y |
DEAD box helicase 3, Y-linked |
increases expression |
EXP |
Tenofovir results in increased expression of DDX3Y mRNA |
CTD |
PMID:37852574 |
|
NCBI chr Y:1,190,042...1,210,699
Ensembl chr Y:1,116,309...1,135,706
|
|
G |
Edn1 |
endothelin 1 |
increases secretion multiple interactions |
ISO |
Tenofovir results in increased secretion of EDN1 protein coenzyme Q10 inhibits the reaction [Tenofovir results in increased secretion of EDN1 protein] |
CTD |
PMID:23640862 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
affects phosphorylation |
ISO |
Tenofovir affects the phosphorylation of EIF2S1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
EXP |
Tenofovir results in decreased expression of FGB mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Gjc2 |
gap junction protein, gamma 2 |
increases expression |
EXP |
Tenofovir results in increased expression of GJC2 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr10:43,962,642...43,971,358
Ensembl chr10:43,962,642...43,970,467
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases secretion multiple interactions |
ISO |
Tenofovir results in increased secretion of HAVCR1 protein Tenofovir inhibits the reaction [cidofovir results in increased secretion of HAVCR1 protein] |
CTD |
PMID:29738843 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions |
EXP |
Tenofovir results in decreased expression of HMOX1 protein Melatonin inhibits the reaction [Tenofovir results in decreased expression of HMOX1 protein] |
CTD |
PMID:33146023 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
affects expression |
ISO |
Tenofovir affects the expression of HSD11B1 mRNA |
CTD |
PMID:20032539 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
affects expression |
ISO |
Tenofovir affects the expression of HSPD1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein] |
CTD |
PMID:36309141 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
EXP |
Tenofovir results in decreased expression of IRF4 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Kdm5d |
lysine demethylase 5D |
increases expression |
EXP |
Tenofovir results in increased expression of KDM5D mRNA |
CTD |
PMID:37852574 |
|
NCBI chr Y:527,069...624,019
Ensembl chr Y:530,401...624,018
|
|
G |
Klf15 |
KLF transcription factor 15 |
decreases expression |
EXP |
Tenofovir results in decreased expression of KLF15 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects expression |
ISO |
Tenofovir affects the expression of LIPE mRNA |
CTD |
PMID:20032539 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
affects expression |
ISO |
Tenofovir affects the expression of LONP1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Lpin1 |
lipin 1 |
decreases expression |
EXP |
Tenofovir results in decreased expression of LPIN1 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
affects phosphorylation |
ISO |
Tenofovir affects the phosphorylation of MAPK8 protein |
CTD |
PMID:27041070 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein |
CTD |
PMID:34118364 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
Tenofovir promotes the reaction [Didanosine results in decreased expression of COX2 mRNA] |
CTD |
PMID:16940060 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
EXP |
Tenofovir results in decreased expression of NFKBIA protein |
CTD |
PMID:27899301 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
Tenofovir results in increased expression of NOS2 mRNA; Tenofovir results in increased expression of NOS2 protein Melatonin inhibits the reaction [Tenofovir results in increased expression of NOS2 protein] |
CTD |
PMID:27899301 PMID:33146023 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases phosphorylation |
ISO |
coenzyme Q10 inhibits the reaction [Tenofovir results in decreased phosphorylation of NOS3 protein] |
CTD |
PMID:23640862 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects expression |
ISO |
Tenofovir affects the expression of NR3C1 mRNA |
CTD |
PMID:20032539 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression |
ISO |
Tenofovir results in increased expression of NT5E mRNA |
CTD |
PMID:24205323 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nt5m |
5',3'-nucleotidase, mitochondrial |
decreases expression |
ISO |
Tenofovir results in decreased expression of NT5M mRNA |
CTD |
PMID:24205323 |
|
NCBI chr10:44,652,845...44,680,549
Ensembl chr10:44,652,975...44,679,150
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression multiple interactions |
EXP |
Tenofovir results in increased expression of PARP1 protein Melatonin inhibits the reaction [Tenofovir results in increased expression of PARP1 protein] |
CTD |
PMID:33146023 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression |
ISO |
Tenofovir affects the expression of PPARG mRNA |
CTD |
PMID:20032539 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in decreased expression of PRKN protein |
CTD |
PMID:31545371 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Tenofovir results in increased expression of PTGS2 mRNA; Tenofovir results in increased expression of PTGS2 protein |
CTD |
PMID:27899301 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization increases expression |
EXP |
Melatonin inhibits the reaction [Tenofovir affects the localization of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of RELA mRNA]; Tenofovir results in increased expression of and results in increased activity of RELA protein |
CTD |
PMID:27899301 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt3 |
sirtuin 3 |
increases expression |
ISO |
Tenofovir results in increased expression of SIRT3 protein |
CTD |
PMID:27041070 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
increases response to substance increases import multiple interactions |
ISO |
SLC22A6 protein results in increased susceptibility to Tenofovir SLC22A6 protein results in increased import of Tenofovir Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to Tenofovir]; SLC22A6 protein results in increased uptake of and results in increased susceptibility to Tenofovir; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:23856525 PMID:25448811 PMID:29738843 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases response to substance increases import |
ISO |
SLC22A8 protein results in increased susceptibility to Tenofovir SLC22A8 protein results in increased import of Tenofovir |
CTD |
PMID:25448811 PMID:29738843 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions increases expression |
ISO EXP |
Tenofovir results in decreased expression of TNF mRNA [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein] Tenofovir results in increased expression of TNF mRNA; Tenofovir results in increased expression of TNF protein |
CTD |
PMID:24205323 PMID:27899301 PMID:36309141 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of TP53 protein Tenofovir results in increased expression of TP53 protein |
CTD |
PMID:31545371 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Usp18 |
ubiquitin specific peptidase 18 |
increases expression |
EXP |
Tenofovir results in increased expression of USP18 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 4:154,471,634...154,499,154
Ensembl chr 4:154,471,592...154,499,144
|
|